In the last few years, the monounsaturated hexadecenoic fatty acids are being increasingly
considered as biomarkers of health with key functions in physiology and pathophysiology …

Non-alcoholic fatty liver disease (NAFLD) is a multifaceted metabolic disorder, whose
spectrum covers clinical, histological and pathophysiological developments ranging from …

Obesity is a primary antecedent to non‐alcoholic fatty liver disease whose cardinal feature is
excessive hepatic lipid accumulation. Although total hepatic lipid content closely associates …

Nonalcoholic fatty liver disease (NAFLD) has become the most common liver disease due to
the global pandemic of metabolic diseases. Dysregulation of hepatic lipid metabolism plays …

Nonalcoholic fatty liver disease (NAFLD) affects approximately 25‐30% population
worldwide, which progresses from simple steatosis to nonalcoholic steatohepatitis (NASH) …

Nonalcoholic fatty liver disease (NAFLD) is defined by a set of hepatic conditions ranging
from steatosis to steatohepatitis (NASH), characterized by inflammation and fibrosis …

Nonalcoholic fatty liver disease (NAFLD) currently represents one of the most common liver
diseases worldwide. Early diagnosis and disease staging is crucial, since it is mainly …

Context Metabolic dysfunction–associated steatotic liver disease (MASLD) is characterized
by the intracellular lipid accumulation in hepatocytes. Excess caloric intake and high-fat …

Purpose Non-alcoholic fatty liver disease (NAFLD) is the hepatic manifestation of the
metabolic syndrome. Particularly morbidly obese patients are at risk of developing …

Abstract Aims (5R)-5-hydroxytriptolide (LLDT-8) is a triptolide analog with excellent
capability against cancers, cerebral ischemic injury and rheumatoid arthritis. Here, we …